Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
 Application for Allogeneic Gamma-Delta T Cell Immunotherapy for Leukemia and Lymphoma - EconoTimes)
NEW YORK, Sept. 19, 2017 -- Incysus, Ltd., a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced the submission of an IND application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 study of expanded and activated allogeneic γδ T cells for patients with blood cancers following haploidentical stem cell transplantation.
“This IND submission is an important milestone for the development of cell therapies that protect the patient from relapse and infection during the critical post-transplant period when the immune system is just beginning to reconstitute,” said Dr. Lawrence Lamb, Professor of Medicine and Director of the University of Alabama at Birmingham (UAB) Cell Therapy Laboratory and a scientific co-founder of Incysus.
Pending FDA acceptance of the IND, the Phase I trial will test the safety and activity of an allogeneic γδ T cell infusion from a donor, as a first step towards a potential off-the-shelf therapy. In collaboration with the UAB, Incysus has developed a scalable and reproducible proprietary γδ T cell manufacturing process using the Miltenyi CliniMACS Prodigy®, an automated, GMP-compliant closed system for cell manufacturing.
“On behalf of the company, I would like to thank our scientific advisors and all of our collaborators at the UAB who helped prepare and submit this IND. We are excited as this novel approach has the potential to boost immune recovery and could represent an important advancement in anti-cancer therapies for patients,” said William Ho, Chief Executive Officer of Incysus.
About Incysus, Ltd.
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit www.incysus.com.
Contact:
Incysus, Ltd
(646) 820-8474
[email protected]
